Healthcare / BiotechnologyKOSDAQ
$2600.00
-50.00 (-1.89%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-7.4B · quality 70.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$229.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-6.1%
↓Gross Margin
14.6%
↓Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+17.9%
FCF CAGR
—
FCF margin
-26.2%
FCF / Net income
1.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $69.56B · net income $-9.23B · FCF $-18.24B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $69.56B | $69.56B | $54.93B | $52.59B | $42.40B |
| Net Income | $-9.23B | $-9.23B | $-22.79B | $-2.30B | $-11.35B |
| EBITDA | $-4.55B | $-4.55B | $-12.87B | $6.63B | $-4.76B |
| EPS | -100.00 | -100.00 | -244.90 | -37.66 | -79.31 |
| Gross Margin | 14.6% | 14.6% | 18.6% | 14.0% | 20.8% |
| Operating Margin | -5.1% | -5.1% | -13.9% | -16.6% | -17.7% |
| Net Margin | -13.3% | -13.3% | -41.5% | -4.4% | -26.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.27 | 0.27 | 0.15 | 0.06 | 0.45 |
| Current Ratio | 1.34 | 1.34 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-18.24B | $-18.24B | $-7.45B | $-2.43B | $-14.40B |
| Returns | |||||
| ROE | -6.1% | -6.1% | -14.5% | -1.4% | -9.7% |
| Valuation | |||||
| EV/EBITDA | — | — | — | 42.17 | — |
| P/B | 1.60 | 1.60 | 7.39 | 1.83 | 3.02 |
| Growth & Yield | |||||
| Revenue Growth | 26.6% | 26.6% | 4.5% | 24.0% | — |
| EPS Growth | 59.2% | 59.2% | -550.3% | 52.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-62.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-244.90 → -100.00
Residual
-62.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.